Based on the key indicators related to Voyager Therapeutics' liquidity, profitability, solvency, and operating efficiency, Voyager Therapeutics is performing exceptionally good at this time. It has a great odds to report excellent financial results in December. At this time, Voyager Therapeutics' Net Working Capital is relatively stable compared to the past year. Key indicators impacting Voyager Therapeutics' financial strength include:
The essential information of the day-to-day investment outlook for Voyager Therapeutics includes many different criteria found on its balance sheet. An individual investor should monitor Voyager Therapeutics' cash flow, debt, and profitability to accurately make informed decisions on whether to invest in Voyager Therapeutics.
Net Income
138.95 Million
Voyager
Select Account or Indicator
Market Cap
Enterprise Value
Price To Sales Ratio
Ptb Ratio
Days Sales Outstanding
Book Value Per Share
Free Cash Flow Yield
Operating Cash Flow Per Share
Stock Based Compensation To Revenue
Capex To Depreciation
Pb Ratio
Ev To Sales
Free Cash Flow Per Share
Roic
Inventory Turnover
Net Income Per Share
Days Of Inventory On Hand
Payables Turnover
Sales General And Administrative To Revenue
Research And Ddevelopement To Revenue
Capex To Revenue
Cash Per Share
Pocfratio
Interest Coverage
Capex To Operating Cash Flow
Pfcf Ratio
Days Payables Outstanding
Income Quality
Roe
Ev To Operating Cash Flow
Pe Ratio
Return On Tangible Assets
Ev To Free Cash Flow
Earnings Yield
Net Debt To E B I T D A
Current Ratio
Tangible Book Value Per Share
Receivables Turnover
Graham Number
Shareholders Equity Per Share
Capex Per Share
Graham Net Net
Revenue Per Share
Interest Debt Per Share
Enterprise Value Over E B I T D A
Price Earnings Ratio
Operating Cycle
Price Book Value Ratio
Price Earnings To Growth Ratio
Days Of Payables Outstanding
Price To Operating Cash Flows Ratio
Price To Free Cash Flows Ratio
Pretax Profit Margin
Ebt Per Ebit
Operating Profit Margin
Effective Tax Rate
Company Equity Multiplier
Return On Capital Employed
Ebit Per Revenue
Quick Ratio
Dividend Paid And Capex Coverage Ratio
Net Income Per E B T
Cash Ratio
Cash Conversion Cycle
Operating Cash Flow Sales Ratio
Days Of Inventory Outstanding
Days Of Sales Outstanding
Free Cash Flow Operating Cash Flow Ratio
Price To Book Ratio
Fixed Asset Turnover
Capital Expenditure Coverage Ratio
Price Cash Flow Ratio
Enterprise Value Multiple
Price Sales Ratio
Return On Assets
Asset Turnover
Net Profit Margin
Gross Profit Margin
Price Fair Value
Return On Equity
Change In Cash
Free Cash Flow
Change In Working Capital
Other Cashflows From Financing Activities
Other Non Cash Items
Capital Expenditures
Total Cash From Operating Activities
Net Income
Total Cash From Financing Activities
End Period Cash Flow
Sale Purchase Of Stock
Investments
Stock Based Compensation
Begin Period Cash Flow
Total Cashflows From Investing Activities
Depreciation
Change To Operating Activities
Other Cashflows From Investing Activities
Change To Netincome
Change To Liabilities
Change To Inventory
Change To Account Receivables
Cash And Cash Equivalents Changes
Cash Flows Other Operating
Total Assets
Short Long Term Debt Total
Other Current Liab
Total Current Liabilities
Total Stockholder Equity
Net Debt
Retained Earnings
Accounts Payable
Cash
Non Current Assets Total
Non Currrent Assets Other
Other Assets
Cash And Short Term Investments
Common Stock Shares Outstanding
Liabilities And Stockholders Equity
Non Current Liabilities Total
Total Liab
Total Current Assets
Short Term Debt
Other Liab
Net Tangible Assets
Property Plant And Equipment Net
Common Stock Total Equity
Short Term Investments
Other Current Assets
Other Stockholder Equity
Deferred Long Term Liab
Long Term Investments
Property Plant And Equipment Gross
Accumulated Other Comprehensive Income
Common Stock
Property Plant Equipment
Current Deferred Revenue
Net Receivables
Retained Earnings Total Equity
Capital Surpluse
Inventory
Non Current Liabilities Other
Net Invested Capital
Net Working Capital
Capital Stock
Capital Lease Obligations
Depreciation And Amortization
Selling General Administrative
Gross Profit
Other Operating Expenses
Operating Income
Ebit
Research Development
Ebitda
Cost Of Revenue
Total Operating Expenses
Income Before Tax
Total Other Income Expense Net
Income Tax Expense
Interest Expense
Total Revenue
Net Income From Continuing Ops
Net Income Applicable To Common Shares
Interest Income
Tax Provision
Net Interest Income
Non Operating Income Net Other
Reconciled Depreciation
Probability Of Bankruptcy
Understanding current and past Voyager Therapeutics Financials, including the trends in assets, liabilities, equity and income are directly related to making proper and timely investing decisions. All of Voyager Therapeutics' financial statements are interrelated, with each one affecting the others. For example, an increase in Voyager Therapeutics' assets may result in an increase in income on the income statement.
Voyager Therapeutics competes with Day One, X4 Pharmaceuticals, Inozyme Pharma, Acumen Pharmaceuticals, and Mereo BioPharma. Voyager Therapeutics, Inc., a gene therapy company, focuses on the development of treatments and next-generation platform technologies. Voyager Therapeutics, Inc. was incorporated in 2013 and is headquartered in Cambridge, Massachusetts. Voyager Therapeut operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 101 people.
Specialization
Health Care, Pharmaceuticals, Biotechnology & Life Sciences
Voyager Therapeutics Key Income Statement Accounts
The reason investors look at the income statement is to determine what Voyager Therapeutics' earnings per share (EPS) will be in order to see if they want to buy more shares or not. For example, if a company earned $20 million in the last quarter and has 100,000 shares outstanding, its EPS is 20 cents. If you find that this number beats analysts' forecasts or is higher than it was from the same period last year, then you might want to buy more of this stock even though its price per share may not have changed.
Comparative valuation techniques use various fundamental indicators to help in determining Voyager Therapeutics's current stock value. Our valuation model uses many indicators to compare Voyager Therapeutics value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Voyager Therapeutics competition to find correlations between indicators driving Voyager Therapeutics's intrinsic value. More Info.
Voyager Therapeutics is rated second in return on equity category among its peers. It is rated first in return on asset category among its peers reporting about 0.15 of Return On Asset per Return On Equity. The ratio of Return On Equity to Return On Asset for Voyager Therapeutics is roughly 6.51 . At this time, Voyager Therapeutics' Return On Equity is relatively stable compared to the past year. Comparative valuation analysis is a catch-all technique that is used if you cannot value Voyager Therapeutics by discounting back its dividends or cash flows. It compares the stock's price multiples to nearest competition to determine if the stock is relatively undervalued or overvalued.
Voyager Therapeutics Systematic Risk
Voyager Therapeutics' systematic risk plays a vital role in portfolio allocation when considering its stock to be added to a well-diversified portfolio. Voyager Therapeutics volatility which cannot be eliminated through diversification, requires returns over the risk-free rate. Over the long run, a well-diversified portfolio provides returns that match its exposure to systematic risk. In this case, investors face a trade-off between expected returns and systematic risk and, therefore, can only reduce a portfolio's exposure to systematic risk by sacrificing expected returns on the portfolio.
The output start index for this execution was ten with a total number of output elements of fifty-one. The Beta measures systematic risk based on how returns on Voyager Therapeutics correlated with the market. If Beta is less than 0 Voyager Therapeutics generally moves in the opposite direction as compared to the market. If Voyager Therapeutics Beta is about zero movement of price series is uncorrelated with the movement of the benchmark. if Beta is between zero and one Voyager Therapeutics is generally moves in the same direction as, but less than the movement of the market. For Beta = 1 movement of Voyager Therapeutics is generally in the same direction as the market. If Beta > 1 Voyager Therapeutics moves generally in the same direction as, but more than the movement of the benchmark.
Voyager Therapeutics Thematic Clasifications
Voyager Therapeutics is part of Pharmaceutical Products investing theme. If you are a theme-oriented, socially responsible, and at the same time, a result-driven investor, you can align your investing habits with your values without jeopardizing your expectations about returns. You can easily create an optimal portfolio of stocks, ETFs, funds, or cryptocurrencies based on a specific theme of your liking. USA Equities from Pharmaceutical Products industry as classified by Fama & French. Fama and French investing themes focus on testing asset pricing under different economic assumptions
This theme covers USA Equities from Pharmaceutical Products industry as classified by Fama & French. Fama and French investing themes focus on testing asset pricing under different economic assumptions. Get More Thematic Ideas
Today, most investors in Voyager Therapeutics Stock are looking for potential investment opportunities by analyzing not only static indicators but also various Voyager Therapeutics' growth ratios. Consistent increases or decreases in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's growth growth rates may not be enough to decide which company is a better investment. That's why investors frequently use static breakdown of Voyager Therapeutics growth as a starting point in their analysis.
Voyager Therapeutics November 30, 2024 Opportunity Range
Along with financial statement analysis, the daily predictive indicators of Voyager Therapeutics help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of Voyager Therapeutics. We use our internally-developed statistical techniques to arrive at the intrinsic value of Voyager Therapeutics based on widely used predictive technical indicators. In general, we focus on analyzing Voyager Stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build Voyager Therapeutics's daily price indicators and compare them against related drivers.
When running Voyager Therapeutics' price analysis, check to measure Voyager Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Voyager Therapeutics is operating at the current time. Most of Voyager Therapeutics' value examination focuses on studying past and present price action to predict the probability of Voyager Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Voyager Therapeutics' price. Additionally, you may evaluate how the addition of Voyager Therapeutics to your portfolios can decrease your overall portfolio volatility.